Dr Leung Oi-ning
Senior Research Fellow
- Y1208
- onleung@polyu.edu.hk
Research Overview
My research interests point towards the unravelling and delineation of molecular mechanisms in liver cancer and the development of novel therapeutic strategies for overriding the resistance to drug treatment in liver cancer.
Education and Academic Qualifications
- Bachelor of Science, The University of Hong Kong
- Master of Medical Sciences, The University of Hong Kong
- Doctor of Philosophy, The University of Hong Kong
Research Interests
Achievements
- Lei MM#, Leung CO#, Lau EY#, Leung RW, Ma VW, Tong M, Lu YY, Huang CY, Zhu QH, Ng IO, Ma S, Lee TK. SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression. JHEP Rep 2022, 5(1):100604. (# contributed equally)
- Mok EH#, Leung CO#, Zhou L, Lei MM, Leung HW, Tong M, Wong TL, Lau EY, Ng IO, Ding J, Yun JP, Yu J, Zhu HL, Lin CH, Lindholm D, Leung KS, Cybulski JD, Baker DM, Ma S, Lee TK. Caspase 3-induced SREBP2 activation drives drug resistance through the promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res 2022, 82(17):3102-3115. (# contributed equally)
- Leung HW#, Leung CO#, Lau EY, Chung KPS, Mok EH, Lei MM, Leung RW, Tong M, Keng VW, Ma C, Zhao Q, Ng IO, Ma S, Lee TK. EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res 2021, 81(12):3229-3240. (# contributed equally)
- Ho NP#, Leung CO#, Wong TL, Lau EY, Lei MM, Mok EH, Leung HW, Tong M, Ng IO, Yun JP, Ma S, Lee TK. The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. Cell Death Dis 2021, 12(2):148. (# contributed equally)
- Mao XW#, Tey SK#, Yeung CLS, Kwong EML, Fung YME, Chung CYS, Mak LY, Wong DKH, Yuen MF, Ho JCM, Pang H, Wong MP, Leung CO, Lee TK, Ma V, Cho WCS, Cao PH, Xu X, Gao Y, Yam JWP. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1. Adv Sci 2020, 7(21): 2002157.
- Leung CO#, Tong M#, Chung KP, Zhou L, Che N, Tang KH, Ding J, Lau EY, Ng IO, Ma S, Lee TK. Overriding adaptive resistance of sorafenib through combination therapy with SHP2 blockade in hepatocellular carcinoma. Hepatology 2020, 72(1):155-68. (# contributed equally)
- Leung CO, Deng W, Ye TM, Ngan HYS, Tsao SW, Cheung ANY, Ziru N, Yuen DCK, Pang RTK, Yeung WSB. MicroRNA-135a-induced formation of CD133+ subpopulation with cancer stem cell properties in cervical cancer. Carcinogenesis 2020., 41(11):1592-1604.
- Leung CO, Mak WN, Kai AK, Chan KS, Lee TK, Ng IO, Lo RC. Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling. Oncotarget 2016, 7(20):29371-86.
- Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, Ng IO, Lo RC. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget 2015, 6(13):10880-92.
- Leung CO, Deng W, Ye TM, Ngan HY, Tsao SW, Cheung AN, Pang RT, Yeung WS. MiR-135a leads to cervical cancer cell transformation through regulation of beta-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis 2014, 35(9):1931-40.
- Pang RT, Leung CO, Lee CL, Lam KK, Ye TM, Chiu PC, Yeung WS. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Dalta-like1. BMC Cancer 2013, 18; 13:25.
- Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, Lee KF, Yeung WS (2010). MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010, 31(6):1037-44.
